Pharmaceutical Technology, Nov 1, 2007 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Nov 1, 2007
Articles
Going Mobile
By Richard W. Padula
Seven Reasons Why Pharmaceutical Makers Are Adopting Mobile Technology
Defragmenting GRC: Confidence and Cost-Efficiency in a Time of Chaos
By Brett Curran
The scope and complexity of GRC requirements are expanding so rapidly that businesses are struggling to fulfill them despite an increased willingness on industry's part to apply additional GRC resources.
Tech Talk: A Q&A with Oracle's Arvindh Balakrishnan
By Michelle Hoffman

The senior director of Oracle's Life Sciences Business Unit tackles some of the technical issues regarding regulatory standardization, software integration, and the trend toward virtualization, among other things.

Do you have something to ask Arvindh Balakrishnan? Click here to submit your questions.

The Challenge in Bioprocess Development: From Data to Knowledge
By Gary Montague , Elaine Martin
The senior director of Oracle's Life Sciences Business Unit tackles some of the technical issues regarding regulatory standardization, software integration, and the trend toward visualization, among other things.
Determining LIMS Functionality, Cost, and ROI: System Architecture Strengths and Limitations
By Ron Kasner
Before any information technology solution can be installed, a company must decide whether applications are going to reside on individual computers at each employee's workstation, on servers within or outside of an organization, or on a vendor's website.
The New Biopharmaceutical Blueprint: Service-Oriented Architecture in Manufacturing
By Pieter Deurinck , Jay DiMare , Michael T. Ricci , Kathleen Martin
More than ever, drug makers need to be fleet and flexible—and they need their software to be the same.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here